Performance of rest myocardial perfusion imaging in the management of acute chest pain in the emergency room in developing nations (PREMIER trial)

J Nucl Cardiol. 2012 Dec;19(6):1146-53. doi: 10.1007/s12350-012-9622-x. Epub 2012 Oct 12.

Abstract

Background: Rest myocardial perfusion imaging (MPI) is effective in managing patients with acute chest pain in developed countries. We aimed to define the role and feasibility of rest MPI in low-to-middle income countries.

Methods and results: Low-to-intermediate risk patients (n = 356) presenting with chest pain to ten centers in eight developing countries were injected with a Tc-99m-based tracer, and standard imaging was performed. The primary outcome was a composite of death, non-fatal myocardial infarction (MI), recurrent angina, and coronary revascularization at 30 days. Sixty-nine patients had a positive MPI (19.4%), and 52 patients (14.6%) had a primary outcome event. An abnormal rest-MPI result was the only variable which independently predicted the primary outcome [adjusted odds ratio (OR) 8.19, 95% confidence interval 4.10-16.40, P = .0001]. The association of MPI result and the primary outcome was stronger (adjusted OR 17.35) when only the patients injected during pain were considered. Rest-MPI had a negative predictive value of 92.7% for the primary outcome, improving to 99.3% for the hard event composite of death or MI.

Conclusions: Our study demonstrates that rest-MPI is a reliable test for ruling out MI when applied to patients in developing countries.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Coronary Syndrome / diagnostic imaging
  • Acute Pain
  • Chest Pain / diagnosis
  • Chest Pain / diagnostic imaging*
  • Developing Countries
  • Diagnosis, Differential
  • Emergency Service, Hospital*
  • Feasibility Studies
  • Female
  • Follow-Up Studies
  • Global Health
  • Humans
  • Male
  • Middle Aged
  • Myocardial Perfusion Imaging*
  • Predictive Value of Tests
  • Radiopharmaceuticals*
  • Rest*
  • Sensitivity and Specificity
  • Technetium Tc 99m Sestamibi*
  • Tomography, Emission-Computed, Single-Photon*

Substances

  • Radiopharmaceuticals
  • Technetium Tc 99m Sestamibi